Mercer Global Advisors Inc. ADV Increases Position in Hologic, Inc. (NASDAQ:HOLX)

Mercer Global Advisors Inc. ADV lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 31.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,220 shares of the medical equipment provider’s stock after purchasing an additional 17,130 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Hologic were worth $5,362,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of HOLX. Innealta Capital LLC purchased a new position in shares of Hologic in the 2nd quarter valued at about $25,000. iA Global Asset Management Inc. purchased a new position in shares of Hologic in the 1st quarter valued at about $37,000. Cranbrook Wealth Management LLC purchased a new position in shares of Hologic in the 2nd quarter valued at about $47,000. Mather Group LLC. purchased a new position in shares of Hologic in the 1st quarter valued at about $48,000. Finally, Massmutual Trust Co. FSB ADV increased its stake in shares of Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 137 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

HOLX stock opened at $81.39 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The business has a 50 day simple moving average of $80.82 and a 200-day simple moving average of $77.12. The firm has a market capitalization of $18.99 billion, a PE ratio of 41.53, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period in the prior year, the business earned $0.93 earnings per share. The business’s revenue was up 2.7% compared to the same quarter last year. Equities research analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Insider Activity at Hologic

In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Hologic news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now owns 10,476 shares in the company, valued at $858,927.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,280 shares of company stock worth $1,469,973. Insiders own 1.75% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Tuesday, September 17th. Stephens reiterated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Evercore ISI boosted their price objective on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 30th. Finally, JPMorgan Chase & Co. boosted their price objective on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Hologic presently has an average rating of “Moderate Buy” and a consensus price target of $87.60.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.